ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Fractures in the major randomized aromatase inhibitor trials

Fractures in the major randomized aromatase inhibitor trials
Trial N/n Follow-up (months) Treatment Clinical fracture rate (%)
AI versus TAM
ATAC[1] 6186/577 68 ANA versus TAM 11.0 versus 7.7 [p<0.0001]
BIG 1-98[2] 4895/352 51 LET versus TAM 8.6 versus 5.8 [p<0.001]
AI after two to three years of TAM
IES[3] 4724/277 58 EXE versus TAM 7.0 versus 5.0 [p = 0.003]
TEAM[4] 9736/415 61 EXE versus TAM 5 versus 3 [p<0.0001]
ABCSG8/ARNO[5] 3224/50 28 ANA versus TAM 2.0 versus 1.0 [p = 0.015]
AI after five years of TAM
MA-17[6] 5187/256 30 LET versus placebo 5.3 versus 4.6 [p = 0.25]
N: number of patients treated; n: total number of fractures; AI: aromatase inhibitor; TAM: tamoxifen; ANA: anastrozole; LET: letrozole; EXE: exemestane.
References:
  1. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365:60.
  2. Coates AS, Keshaviah A, Thürlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007; 25:486.
  3. Coleman RE, Banks LM, Girgis SI, et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): A randomised controlled study. Lancet Oncol 2007; 8:119.
  4. van de Velde CJ, Rea D, Seynaeve C, et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): A randomised phase 3 trial. Lancet 2011; 377:321.
  5. Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005; 366:455.
  6. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005; 97:1262.
Graphic 70977 Version 2.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟